Resources

During the launch meeting for the Learning Network for Countries in Transition (LNCT),  participants had the opportunity to ask representatives from partner organizations their questions about partner policy, vaccine availability, and vaccine financing, among other topics.

These programmatic policies set out principles for Gavi-supported countries and programs to ensure that Gavi support is efficient,

In this blog post, Robert Hecht and Sarah Bennet describe global health transitions and explain the reasons why they are happening now;

This article discusses some of the challenges facing countries currently transitioning out of Gavi support, how Gavi’s policies have evolved to help manage the risks involved in this process, and the lessons learned from this experience.

Since the mid-2000s low- and lower-middle-income countries have been focusing on developing and using evidence for immunization policy making,

Sixteen countries are currently scheduled to ‘graduate’ from GAVI assistance by 2018. Five of these countries were chosen for ‘transition planning’ support from GAVI and other partners in 2012.

Immunization is one of the “best buys” in global health. However, for the poorest countries,

Since 2000, GAVI provided essential support for an unprecedented increase in the use of hepatitis B (HepB) and Haemophilus influenzae (Hib) containing vaccines in resource poor countries. This increase was supported with significant funding from international donors, intended to be time-limited. To assess the sustainability of this important expansion of the global access to vaccines, the authors of this article reviewed supply chains, financial resources for procurement and decision-making in countries that introduced hepatitis B or Hib vaccines with GAVI support.